ArticleBMC psychiatry2020
Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019.
Article in BMC psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Efficacy of repetitive transcranial magnetic stimulation combined with cognitive behavioral therapy for depression: a systematic review and meta-analysis.Frontiers in psychology · 2026Pooled it
- Real-World Antidepressant Prescribing Patterns and Comparative Safety Outcomes of Commonly Prescribed Antidepressants in Patients with Depressive Disorder: A Multicenter OMOP-CDM Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Real‑World Clinical Characterization of Major Depressive Disorder and Treatment‑Resistant Depression Supported by Natural Language Processing: Multicenter Observational Study From the MOOD Project.Interactive journal of medical research · 2026Article
- Patterns of antidepressant treatment changes among adults with major depressive disorder in Northwest Ethiopia: a hospital-based cross-sectional study.Therapeutic advances in psychopharmacology · 2026Article
- Real-World Antidepressant Treatment Persistence in Children and Adolescents with Major Depressive Disorder in Japan: A Retrospective Nationwide Claims-Based Study.Neuropsychiatric disease and treatment · 2026Article
- Treatment persistence and modification patterns of SSRIs in children and adolescents with depression: a nationwide population-based study in South Korea.BMC psychiatry · 2025Article
- Maintenance pharmacotherapy after electroconvulsive therapy in inpatients with major depressive disorder: 198 prescriptions in a real-world clinical setting.BMC psychiatry · 2025Article
- Real-world pharmacotherapy treatment patterns among patients diagnosed with postpartum depression in the United States.BMC psychiatry · 2025Article
- Utility of Treatment Pattern Analysis Using a Common Data Model: A Scoping Review.Healthcare informatics research · 2025Article
- Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder.Frontiers in pharmacology · 2025Article
- Age-Dependent Sex Differences in the Prevalence of Selective Serotonin Reuptake Inhibitor Treatment: A Retrospective Cohort Analysis.Journal of women's health (2002) · 2023Article
- Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States.Journal of managed care & specialty pharmacy · 2023Article
- Investigation of the pharmacological treatment patterns of Chinese patients with major depressive disorder under real-world settings using multi-channel sequence analysis.Frontiers in psychiatry · 2023Article
- Annual costs among patients with major depressive disorder and the impact of key clinical events.Journal of managed care & specialty pharmacy · 2022Article
- Observational
- Heterogeneity in treatment outcomes and incomplete recovery in first episode psychosis: does one size fit all?Translational psychiatry · 2022Review
- Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes.Biological psychiatry · 2022Article
- Unsupervised Machine Learning to Identify Depressive Subtypes.Healthcare informatics research · 2022Article
- Care pathways for people with major depressive disorder: a European Brain Council Value of Treatment study.European psychiatry : the journal of the Association of European Psychiatrists · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundUnderstanding how patients are treated in the real-world is vital to identifying potential gaps in care. We describe the current pharmacologic treatment patterns for the treatment of depression.
methodsPatients with depression were identified from four large national claims databases during 1/1/2014-1/31/2019. Patients had ≥2 diagnoses for depression or an inpatient hospitalization with a diagnosis of depression. Patients were required to have enrollment in the database ≥1 year prior to and 3 years following their first depression diagnosis. Treatment patterns were captured at the class level and included selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, other antidepressants, anxiolytics, hypnotics/sedatives, and antipsychotics. Treatment patterns were captured during all available follow-up.
resultsWe identified 269,668 patients diagnosed with depression. The proportion not receiving any pharmacological treatment during follow-up ranged from 29 to 52%. Of the treated, approximately half received ≥2 different classes of therapy, a quarter received ≥3 classes and more than 10% received 4 or more. SSRIs were the most common first-line treatment; however, many patients received an anxiolytic, hypnotic/sedative, or antipsychotic prior to any antidepressive treatment. Treatment with a combination of classes ranged from approximately 20% of first-line therapies to 40% of fourth-line.
conclusionsMany patients diagnosed with depression go untreated and many others receive a non-antidepressant medication class as their first treatment. More than half of patients received more than one type of treatment class during the study follow up, suggesting that the first treatment received may not be optimal for most patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.